Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Inv (1) antigen distribution was studied in 568 normal subjects and in 354 hematological patients in the Armenian population. Inv (1) antigen was detected in 16.7% of the normal Armenians studied. The incidence rate of Inv (1) factor does not depend on the distribution of phenotypes of ABO system, rhesus factor (D), and the sex of the subjects investigated. Inv (1) antigen incidence rate in patients with acute leukemia, chronic lymphocytic leukemia, iron deficiency anemia, lymphogranulomatosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia was similar to that in the control, and only patients with chronic myeloid leukemia had significantly decreased levels of Inv (1) antigen: 6.8% as compared to 16.7% in the population.
 ...
PMID:[Antigenic composition of serum proteins of the Inv system in normal conditions and in patients with hematologic diseases among the Armenian population]. 138 57

Serum erythropoietin (Epo) titers in patients with various hematological malignancies and related diseases were determined by radioimmunoassay. Serum Epo titer was inversely correlated with hemoglobin concentration in iron deficiency anemia, aplastic anemia, myelodysplastic syndromes (MDS), acute leukemia, malignant lymphoma, multiple myeloma and myelofibrosis, but there was no correlation between serum Epo titer and hemoglobin concentration in chronic myelogenous leukemia or polycythemias. Serum Epo titers in aplastic anemia were much higher than those in iron deficiency anemia. Serum Epo titers in MDS, malignant lymphoma and multiple myeloma differed considerably among patients. Serum Epo titers in untreated polycythemia vera were significantly lower than in treated polycythemia vera or secondary polycythemia.
 ...
PMID:Serum erythropoietin titers in hematological malignancies and related diseases. 146 Mar 22

Cell cycle phases of bone marrow cells from 8 patients with iron deficiency anemia (IDA), 8 aplastic anemia (AA), 30 myelodysplastic syndrome (MDS), 41 acute leukemia (AL) before treatment, 8 acute leukemia in relapse, 17 acute leukemia in complete remission (CR), 12 chronic myelogenous leukemia (CML) and 4 chronic lymphocytic leukemia (CLL) were analysed with flow cytometry. The proportions of phases of S. G2 M in patients with IDA, refractory anemia, and refractory anemia with ring sideroblast were similar to these in normal controls (P > 0.05). However, they were significantly lower in patients with AA, refractory anemia with excess of blast (RAEB) and transformed RAEB than those in normal controls (P < 0.01, respectively), and CML patients than in normal controls (P < 0.05). The S G2M% was apparently higher in patients with CML than that in CLL (P < 0.01). But, there was no difference between in ALL and ANLL (P > 0.05). It was higher in patients with AL in CR and in relapse than AL before treatment (both P < 0.01). It was still lower in the former than that in normal controls. (P < 0.05). The clinical significance of cell cycle status was also discussed in this paper.
 ...
PMID:[Flow cytometric analysis of bone marrow cell cycles in patients with hematologic diseases]. 147 30

We evaluated changes in red cell distribution width-standard deviation (RDW-SD) measured using a multiple parameter automated hematology analyzer E 4000 in patients with polycythemia vera (PV). Patients with iron deficiency anemia, those with chronic myelogenous leukemia, those with primary thrombocythemia, and normal subjects were examined as controls. In the patients with PV, as in those with the other 3 diseases, RDW-SD tended to be higher than in the normal controls when red blood cell counts were high. The RDW-SD in patients with PV transiently increased following administration of a myelosuppressive, which corresponded to the transition period from microcytes to normal blood cells. It was even higher during the polycythemic period than during the myelofibrotic period. This may be associated with hematopoietic abnormality due to extramedullary hematopoiesis. RDW-SD seems to well reflect the pathologic status of PV.
 ...
PMID:[Clinical significance of red cell distribution width in polycythemia vera]. 260 51

We reviewed 2110 bone marrow aspirations from the same number of patients to establish the incidence and associations of peripheral and bone marrow basophilia. Of these, 125 cases of marrow basophilia (5.9% incidence) and 63 cases of peripheral basophilia (3.0% incidence) were identified. There were 33 patients with simultaneous marrow and peripheral basophilia, which was only significantly associated with chronic myelogenous leukemia (24 cases). Isolated peripheral basophilia was rarely seen (30 patients, 1.4% incidence) and it did not reflect any significant pathologic association. Marrow basophilia was significantly present in chronic myeloproliferative disorders, idiopathic myelodysplasia, certain erythrocyte disorders, such as iron deficiency anemia, and aplastic anemia. The incidence of marrow basophilia in patients with lymphoma, acute leukemia, or solid carcinoma was not significantly different from what it would be as a chance occurrence. Our findings suggest that marrow basophilia is a specific, but not sensitive, marker of myeloproliferative and dysmyelopoietic syndromes.
 ...
PMID:Incidence and clinical significance of peripheral and bone marrow basophilia. 350 57

Plasma and urine levels of cyclic adenosine 3',5'-monophosphate (cAMP) and of cyclic guanosine 3',5'-monophosphate (cGMP) were measured in 35 normal subjects, in 24 patients with nonneoplastic diseases (iron deficiency anemia, peptic ulcer, and cholelithiasis), and in 50 leukemic patients. The leukemic group included patients with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. All patients were recently diagnosed and untreated, except for 5 patients with blastic transformation of chronic myelogenous leukemia who had been previously treated. There were no significant differences in plasma and urine cyclic nucleotide levels between normal subjects and patients with nonneoplastic diseases. In leukemic patients, plasma and urine cAMP levels were similar to those of normal subjects, whereas plasma and urine cGMP levels were markedly elevated. There were no significant differences in cGMP values between the various types of leukemia. After starting treatment, plasma cyclic nucleotide levels were periodically measured in 21 of the patients with acute leukemia; cGMP levels were normalized in all the 16 subjects who attained complete remission, whereas both cAMP and cGMP levels were apparently unaffected in the patients who did not respond to treatment. This suggests that plasma or urine cGMP could be used as an additional parameter to monitor the patient's response to treatment.
 ...
PMID:Plasma and urine cyclic nucleotide levels in patients with acute and chronic leukemia. 629 36

We examined the fine structural distribution of glycogen particles in the cells of the erythrocyte series from thirty individuals with or without hematological disorders using the periodic acid-thiocarbo hydrazide-silver proteinate (PA-TCH-SP) technique, which is known to extend PAS staining to the ultrastructural level. In diseases exhibiting dyserythropoiesis, such as refractory anemia with excess of blasts (RAEB) and juvenile chronic myelocytic leukemia (JCML), glycogen particles remarkably increased. In diseases showing hypererythropoiesis such as iron deficiency anemia, hemolytic anemia, or in cells obtained from very small premature infants, an increase in glycogen particles was observed in most cases. Compared to the PAS staining technique, which also utilizes the periodic acid reaction, the PA-TCH-SP technique appears to be more sensitive for visualizing glycogen particles in PAS negative cells, in addition to its capability of demonstrating the distribution of periodate reactive substance at the fine structural level.
 ...
PMID:Ultracytochemistry of glycogen particles in human erythroblasts. Semiquantitative observation. 659 2

Cell cycle stage distribution of bone marrow cells was studied at flow cytometry in 137 hematological patients. They had acute lymphoblastic leukemia, acute myeloblastic leukemia, lymphosarcoma with leukemization, blast crisis of chronic myeloid leukemia, iron deficiency anemia, pernicious anemia, autoimmune hemolytic anemia, aplastic anemia (31, 34, 18, 12, 17, 8, 9, 8 cases, respectively). It was found that in leukemia, and to a lesser degree in anemia, stability of the cell cycle was impaired. In leukemia onset, recurrence and remission, the proportion S/(G2+M) appeared increased evidencing defective DNA synthesis by myelokaryocytes and ineffective hemopoiesis. Similar changes were seen in pernicious and aplastic anemia.
 ...
PMID:[Changes in the stability of the parameters of the bone marrow cell cycle in hematologic diseases]. 942 52

A retrospective study of 126 patients with extreme thrombocytosis (defined as a platelet count > or = 1,000 x 10(9)/L) was performed during a five-year period (June 1994-June 1999). The aim of this study was to determine the etiology and to evaluate the clinical consequences of extreme thrombocytosis. Seventy patients (55.5%) had reactive thrombocytosis (RT) with an age range of 43 +/- 2.2 years, 56 (44.5%) had chronic myeloproliferative disorders (MPD) with an age range of 53 +/- 2.4 years. Underlying causes of RT were malignancy (25/70 or 35.7%), infection (16/70 or 22.9%), postsplenectomized beta-thalassemia/Hb E (11/70 or 15.7%), inflammation (12/70 or 17.1%), iron deficiency anemia (6/70 or 8.6%). Duration post splenectomy in our beta-thalassemia/Hb E patients ranged from 4 months to 21 years, with a median of 10 years. Subtypes of our MPD cases were chronic myeloid leukemia (30/56 or 53.6%), essential thrombocytosis (18/56 or 32.1%), polycythemia vera (4/56 or 7.1%), agnogenic myeloid metaplasia (3/56 or 5.4%) and unclassified MPD (1/56 or 1.8%). Bleeding and thrombotic tendency were respectively noted in 7 (12.5%) and 2 (3.6%) of MPD patients. Two patients of the MPD group (3.6%) experienced both bleeding and thrombotic episodes. One patient (1.4%) of the RT group developed vasculitis-associated thrombosis. However, none of the patients in the RT group had bleeding complications. Extreme thrombocytosis was not a rare condition in a university hospital population, and bleeding and/or thrombotic complication was more common in the MPD group.
 ...
PMID:Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis. 1086 14

The pathogenesis of polycythemia vera (PV), a disease involving a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin (TPO) is a newly characterized hematopoietic growth factor which regulates the production of multipotent hematopoietic progenitor cells as well as platelets. To evaluate the possibility that an abnormality in TPO-mediated signal transduction might be involved in the pathogenesis of PV, we examined TPO-induced protein tyrosine phosphorylation using platelets as a surrogate model system. Platelets were isolated from the blood of patients with PV as well as from patients with other chronic myeloproliferative disorders and control subjects. Impaired TPO-mediated platelet protein tyrosine phosphorylation was a consistent observation in patients with PV as well as those with idiopathic myelofibrosis (IMF), in contrast to patients with essential thrombocytosis, chronic myelogenous leukemia, secondary erythrocytosis, iron deficiency anemia, hemochromatosis, or normal volunteers. Thrombin-mediated platelet protein tyrosine phosphorylation was intact in PV platelets as was expression of the appropriate tyrosine kinases and their cognate substrates. However, expression of the platelet TPO receptor, Mpl, as determined by immunoblotting, chemical crosslinking or flow cytometry was markedly reduced or absent in 34 of 34 PV patients and also in 13 of 14 IMF patients. Impaired TPO-induced protein tyrosine phosphorylation in PV and IMF platelets was uniformly associated with markedly reduced or absent expression of Mpl. We conclude that reduced expression of Mpl is a phenotypic characteristic of platelets from patients with PV and IMF. The abnormality appears to distinguish PV from other forms of erythrocytosis and may be involved in the platelet function defect associated with PV.
 ...
PMID:A novel thrombopoietin signaling defect in polycythemia vera platelets. 1101 90


1 2 Next >>